Trial Profile

Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 2 (ICAC-30)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Feb 2026 Results presented in the American Academy of Allergy, Asthma & Immunology (AAAAI) Media Release.
22 May 2024 Results (n=290 in subgroups) assessing the efficacy of mepolizumab in urban children with exacerbation-prone asthma and greater than or equal to 150 blood eosinophils /microliter were presented at the 120th International Conference of the American Thoracic Society.
22 May 2024 Results (n=53) of analysis of mechanisms of asthma exacerbations in the context of anti-IL5 treatment, an in-depth analysis of sputum eosinophil marker expression using mass cytometry presented at the 120th International Conference of the American Thoracic Society.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com